Search Results

The purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (cLBP) compared to a group of participants who are engaging in integrative health practices. The multi-modal device will include a combination of electrical stimulation, auditory stimulation, and integrative-health techniques, including mindfulness breathing, health coaching, and reflective journaling. The multi-modal device creation is based on prior knowledge in lower back pain treatment, which includes electrical stimulation of the back (Transcutaneous Electrical Nerve Stimulator or TENS) and integrative health modalities. Findings from this usability pilot study could help refine the approach and the multi-modal device for a future intervention study in cLBP participants.

Researchers hope that using Fisetin, an antioxidant, will reduce inflammation in the body caused by sepsis, which could help your body and organs have more time to recover. Placebo in this study will be something that looks similar to the study treatment, but does not contain any active drug. Everyone will receive 4 pills, but your group will determine how many of the pills are Fisetin. Researchers will look at the potential effects Fisetin or placebo has on inflammation in the body and how sick participants are at 7 days and 28 days.

We are exploring ways to promote healthy lifestyles during stroke rehabilitation using a web-based rehabilitation program. The purpose of this study is to compare two intervention approaches: teleABLE and Healthy Lifestyles Education. Both interventions are delivered using video visits, so participants can complete all study activities from home

How strong is your squeeze? We’re inviting kids aged 2-12 to test their grip and help us establish new standards for hand strength. Your contribution allows our team to create more inclusive, accurately calibrated technology that works for everybody. Stop by the Minnesota State Fair Research Building for a Tyrannosaurus Flex to help us find the Fair-ly Normal Grip and help us build the future of interactive play!

We are doing this study because we want to find out if observation is as good as the usual care for breast cancer. The usual approach for patients with early-stage triple-negative breast cancer (TNBC) who receive preoperative chemotherapy plus pembrolizumab is to continue to receive FDA-approved pembrolizumab for up to 27 weeks after surgery. Participants will either get pembrolizumab for up to 27 weeks, or will not receive any treatment and will be observed for up to 27 weeks. We will continue to follow participants every 6 months for 5 years and watch for side effects or cancer coming back. After that, participants will be checked every year for a total of 10 years after the study.

This study is testing an “investigational” drug referred to as peptide alarm therapy (PAT) that was specially made for this study. PAT is using the peptide to stimulate the immune system for people who have failed prior treatment with a PD-1/PD-L1 inhibitor. Examples of PD-1/PD-L1 inhibitors are pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). The goal of the 1st part of the study is to identify an acceptable, safe dose of PAT and up to 3 dose levels of PAT will be tested. If dose level 3 is reached without toxicity, it becomes the dose used for the next part of the study. In the 2nd part of the study, additional patients are treated at the PAT dose identified as safe in the 1st part to gain additional safety information and provide an initial estimate of anti-cancer effect.

The research aspect of this trial is the use of a new machine to remove specific lymphocytes from the donor’s peripheral blood stem cells (PBSCs). This is called T cell receptor alpha/beta T cell depletion. This machine does such a good job at removing the unwanted donor T cells, and as a result we think patients will need fewer drugs to suppress their immune system.

We want to find out whether lifileucel is safe and works in treating untreated, unresectable or metastatic melanoma. Lifileucel is a type of medicine, known as immunotherapy, that uses your body’s immune system to fight cancer. Lifileucel is also called “tumor infiltrating lymphocytes” (TIL) and is made up of specialized white blood cells known as lymphocytes or “T cells” obtained from a piece of your tumor. T cells are a part of your immune system that help your body fight against infections and diseases including fight cancer.

The purpose of this study is to assess whether JNJ-87189401 given in combination with pasritamig (JNJ-78278343) to men with metastatic castration-resistant prostate cancer (also known as mCRPC) can cause side effects, and to find doses for the two drugs when given in combination. Side effects are unexpected or unwanted reactions from receiving the study drugs. Additionally, the study will look at how long JNJ-87189401 and pasritamig stay in the body, how they act on the body, and how the body responds to them.

This study is following high school and first-year university students to learn more about Epstein-Barr virus (EBV) infection. We want to learn more about how common EBV is, how often new infections occur, and what factors may be linked to infections. The results may help us plan future EBV studies.

This study looks at decision-making and brain function in people with psychosis spectrum disorders, such as schizophrenia. By joining this study, you can help us better understand how the brain makes decisions in psychosis. What we learn may help guide better treatments for people with psychosis in the future.

The upfront treatment for astrocytoma is surgery, radiation therapy, and chemotherapy. There is currently no standard therapy for when the astrocytoma has returned (recurs) or re-grows (progresses). This study uses the investigational drug FT536, a cell therapy that stimulates the immune system into action to treat astrocytoma that has returned or regrown. FT536 is a type of cell therapy made up of “natural killer” or NK cells, a type of immune blood cell that are known to attack cancer cells. The primary purpose of this study is to identify a safe dose of FT536 cells when given as an intratumoral injection and to identify the side effects of treatment with FT536. Another purpose of this study is to understand how FT536 alters the immune system in the brain and body.

This study is testing a radioactive treatment for adults with advanced melanoma that has spread, cannot be removed by surgery, or has gotten worse after prior treatment. We want to learn how safe the treatment is and how well it may work. By taking part, participants may help us learn whether this could become a useful treatment option for people with advanced melanoma.

The purpose of this study is to evaluate how TAK-505 works in people with certain advanced solid tumors, including stomach, colorectal, lung, and head and neck cancers. The study will test TAK-505 at different dose levels to understand how it is tolerated, how it behaves in the body, and to help determine the dose that provides the best balance of effect and side effects for future studies.

This study is for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that cannot be removed with surgery or has spread to other parts of the body. Participants must have previously received one standard chemotherapy treatment for advanced disease. Researchers are studying an investigational medication called nanvuranlat to see if it is safe and effective for treating advanced biliary tract cancer. The study will compare nanvuranlat with standard treatment to learn how well it works, monitor its safety, and better understand how it affects the body and the cancer.

The purpose of this study is to test a new CAR T-cell therapy called AZD0120 in adults with multiple myeloma that has returned or has not responded to previous treatments. Researchers want to learn whether this therapy is safe, determine the best dose to use, and see how well it works against the cancer. The study will also look at how the treatment affects the immune system and participants’ quality of life.

This study is for adults with large B-cell lymphoma whose cancer responded to standard treatment but still shows small amounts of disease on a specialized blood test. Participants will be randomly assigned to receive either an investigational CAR T-cell therapy or standard follow-up observation to compare safety and how well each approach helps prevent the lymphoma from returning.

The purpose of this study is to evaluate the long-term safety and ability of a transplant with gene modified stem cells (autologous stem cell transplant) to treat sickle cell disease. Participants must have received investigational gene therapy with bb1111 in a clinical study sponsored by bluebird bio. There is no additional treatment associated with this study as this is a long-term follow-up study.

How do you learn best, by watching or reading? With the rise of short videos on apps like TikTok, we’re studying how people prefer to learn about health. Participants at the Minnesota State Fair Research Building will learn about kidney stones either through a quick video or a simple pamphlet, like one you might get at a doctor’s office. Then, they’ll take a brief quiz and share their preferences. This study helps us understand the best ways to share health information, so patients feel more confident and empowered in their care.

The Blue Ribbon Bladder Study is a project just for women. We want to learn more about how women manage everyday bladder issues and use what we learn to find better ways to support bladder health. Visit us at the Minnesota State Fair Research Building to learn more and share your experience! Help us make bladder health an easier part of everyday self-care.

Help researchers at the Minnesota State Fair Research Building learn how people naturally hold a pen while writing. This information may improve therapies that support handwriting skills.

The UMN Neuropsychology team invites you to the Minnesota State Fair Research Building to complete a brief health survey and a couple of quick cognitive tests to help us learn how different generations, from Silent and Boomers to Millennials and Gen Z, complete two executive functioning tasks.

This study is for adults with APOL1-Mediated Kidney Disease (AMKD). Researchers are testing a study medicine called AZD2373 to learn if it may help treat this type of kidney disease and how safe it is to take.

The goal of this study is to evaluate the combination of cabozantinib and nivolumab in people with advanced melanoma or squamous cell head and neck cancer. Researchers want to learn whether these drugs can help shrink or stabilize cancer and whether certain tumor biomarkers may help predict how well patients respond to treatment.

Share what you know and think about dental therapists and oral health at the Minnesota State Fair Research Building. Your feedback will help improve communication and access to dental care.

How does your relationship handle stress? Complete a brief survey at the Minnesota State Fair Research Building about communication, coping, and connection to help researchers learn what keeps relationships strong.

Swab and rinse your mouth to help researchers study the bacteria that affect oral health. Participate in a quick activity at the Minnesota State Fair Research Building and take home a prize!

The aim of this study is to obtain newborn blood spots (NBS) and tumor specimens for children and adolescents diagnosed with malignant neoplasms.

This study is testing whether a single additional treatment of radiation therapy, called maintenance radiotherapy, is safe and feasible for adults who have recently been diagnosed with glioblastoma (GBM). Participants will first receive their usual treatment for GBM, including surgery, radiation therapy, and the chemotherapy drug temozolomide. About one month after completing standard radiation therapy, participants will receive one additional treatment of radiation therapy. The study will also look at changes in certain immune cells before and after the additional radiation treatment. Participants will continue their usual follow-up care every 2 to 4 months for up to 5 years after the additional treatment.

Play Tetris while researchers at the Minnesota State Fair Research Building measure your brain activity to better understand how the brain works during gameplay.